mRNA Ç÷§Æû ½ÃÀå : mRNA À¯Çü, mRNA ºÐÀÚ, ¿ëµµ, ÀûÀÀÁõ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)
mRNA Platform Market by mRNA Type (Nucleoside-Modified mRNA, Unmodified mRNA), mRNA Molecule (Monocistronic mRNA, Polycistronic mRNA), Application, Indication, End-User - Global Forecast 2025-2030
»óǰÄÚµå : 1602272
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 182 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

mRNA Ç÷§Æû ½ÃÀåÀº 2023³â¿¡ 135¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 163¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 21.44%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 527¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

mRNA Ç÷§ÆûÀº »ý¸í°øÇÐ ¹× Á¦¾à ºÐ¾ßÀÇ Çõ½ÅÀûÀÎ ºÐ¾ß·Î, ÁÖ·Î Ä¡·áÁ¦¿Í ¹é½Å¿¡ Àû¿ëµÇ´Â ¸Þ½ÅÀú RNA(mRNA) ±â¼ú °³¹ß¿¡ °ü¿©Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù mRNA COVID-19 ¹é½ÅÀÇ ±Þ¼ÓÇÑ °³¹ß ¹× ¹èÆ÷´Â ±× Çʿ伺À» °­Á¶ÇÏ°í ¹é½Å »ý»êÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù. ¹é½Å»Ó¸¸ ¾Æ´Ï¶ó mRNAÀÇ ÀÀ¿ë ¹üÀ§´Â ¸ÂÃãÇü ÀÇ·á, ´Ü¹éÁú ´ëü¿ä¹ý, ¾Ï ¹× À¯Àü¼º Áúȯ°ú °°Àº Áúº´ Ä¡·á¿¡µµ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ë »ê¾÷¿¡´Â ÁÖ·Î Á¦¾àȸ»ç, »ý¸í°øÇÐ ±â¾÷, ¿¬±¸°³¹ß ¹× Ä¡·á °³¹ß¿¡ Á¾»çÇÏ´Â ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Æ÷ÇԵ˴ϴÙ. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ±â¼ú ¹ßÀü, ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¿¡ ´ëÇÑ ´ëÀÀ ´É·Â, »ý¸í°øÇп¡ ´ëÇÑ ÅõÀÚ Áõ°¡ÀÔ´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ·Î´Â Àç»ýÀÇÇÐ, ¸¸¼ºÁúȯ °ü¸®¿Í °°Àº ºñ ±âÁ¸ ¿ëµµ¿¡¼­ÀÇ mRNAÀÇ Å½»ö°ú µ¿¹°¿ë ¿ëµµ¿Í °°Àº Àΰ£ ÀÇ·á ÀÌ¿ÜÀÇ ºÐ¾ß¿¡¼­ÀÇ mRNA ÀÌ¿ë »ç·ÊÀÇ È®´ë°¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ÀÌÇØ°ü°èÀÚµéÀº ¿¬±¸ ÆÄÆ®³Ê½Ê°ú »ý»ê ºñ¿ëÀ» Àý°¨Çϰí Àü´Þ ¼Ö·ç¼ÇÀ» °­È­ÇÒ ¼ö ÀÖ´Â ±â¼ú Çõ½Å¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 135¾ï 2,000¸¸ ´Þ·¯
ÃßÁ¤³â[2024] 163¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 527¾ï 1,000¸¸ ´Þ·¯
CAGR(%) 21.44%

±×·¯³ª ½ÃÀåÀº ±ÔÁ¦ À庮, ³ôÀº °³¹ß ºñ¿ë, mRNA º¸°ü ¹× ¿î¼ÛÀÇ ¹°·ù º¹À⼺, ±âÁ¸ Ä¡·áÁ¦¿ÍÀÇ °æÀï µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÁöÀûÀç»ê±Ç À庮°ú °ø±Þ¸Á Ãë¾à¼ºµµ Å« Á¦¾à¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í Æ¯È÷ mRNA Á¦Á¦ÀÇ ¾ÈÁ¤¼º Çâ»ó, ÁöÁú ³ª³ëÀÔÀÚ¿Í °°Àº »õ·Î¿î Àü´Þ ½Ã½ºÅÛ °³¹ß, ´ë±Ô¸ð Á¦Á¶ ±â¼úÀÇ ÃÖÀûÈ­ µî ±â¼ú Çõ½ÅÀÇ °¡´É¼ºÀº ¹«±Ã¹«ÁøÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº Áúº´ °ü¸® ¹× Ä¡·á ¹æ¹ýÀ» ÀçÁ¤ÀÇÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¸Å¿ì ¿ªµ¿ÀûÀ̸ç, ºü¸¥ ±â¼ú º¯È­, ³ôÀº »ó¾÷Àû °ü½É, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß Ȱµ¿ÀÌ Æ¯Â¡ÀÔ´Ï´Ù. Áö¼Ó°¡´ÉÇÑ ¼ºÀåÀ» À§ÇØ ±â¾÷Àº ¿¬±¸¸¦ °¡¼ÓÈ­ÇÏ°í ±ÔÁ¦ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­ÇÏ´Â °øµ¿ »ýŰ迡 ÃÊÁ¡À» ¸ÂÃß°í, »õ·Î¿î mRNA ±â¹Ý Çõ½Å ½ÃÀå ÁøÀÔÀ» ÃËÁøÇϱâ À§ÇØ Á¤Ã¥ ÀÔ¾ÈÀÚµé°ú Çù·ÂÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â mRNA Ç÷§Æû ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® ÆÄ¾ÇÇϱâ

mRNA Ç÷§Æû ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces: mRNA Ç÷§Æû ½ÃÀå °ø·«À» À§ÇÑ Àü·« Åø

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : mRNA Ç÷§Æû ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼® : mRNA Ç÷§Æû ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº mRNA Ç÷§Æû ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® mRNA Ç÷§Æû ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

mRNA Ç÷§Æû ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º mRNA Ç÷§Æû ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â mRNA Ç÷§Æû ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ mRNA Ç÷§Æû ½ÃÀå ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

mRNA Ç÷§Æû ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå mRNA Ç÷§Æû ½ÃÀå : mRNA À¯Çüº°

Á¦7Àå mRNA Ç÷§Æû ½ÃÀå : mRNA ºÐÀÚº°

Á¦8Àå mRNA Ç÷§Æû ½ÃÀå : ¿ëµµº°

Á¦9Àå mRNA Ç÷§Æû ½ÃÀå : ÀûÀÀÁõº°

Á¦10Àå mRNA Ç÷§Æû ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ mRNA Ç÷§Æû ½ÃÀå

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ mRNA Ç÷§Æû ½ÃÀå

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ mRNA Ç÷§Æû ½ÃÀå

Á¦14Àå °æÀï ±¸µµ

±â¾÷ ¸®½ºÆ®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The mRNA Platform Market was valued at USD 13.52 billion in 2023, expected to reach USD 16.33 billion in 2024, and is projected to grow at a CAGR of 21.44%, to USD 52.71 billion by 2030.

The mRNA platform is a transformative segment within biotechnology and pharmaceuticals, involving the development of messenger RNA (mRNA) technologies for applications primarily in therapeutics and vaccines. Its necessity has been underscored recently by the rapid development and deployment of mRNA COVID-19 vaccines, showcasing its ability to accelerate vaccine production. Beyond vaccines, mRNA's application scope extends to personalized medicine, protein replacement therapies, and treatment of diseases such as cancer and genetic disorders. End-use industries predominantly include pharmaceuticals, biotech firms, and healthcare providers engaged in research and therapeutic development. Market growth is primarily driven by technological advancements, the ability to address unmet medical needs, and increasing investment in biotech. Emerging opportunities include exploring mRNA for non-traditional uses like regenerative medicine and chronic disease management, and expanding mRNA use cases outside of human medicine, such as in veterinary applications. To capitalize on these opportunities, stakeholders should invest in research partnerships and technological innovations that reduce production costs and enhance delivery solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 13.52 billion
Estimated Year [2024] USD 16.33 billion
Forecast Year [2030] USD 52.71 billion
CAGR (%) 21.44%

However, the market faces challenges such as regulatory hurdles, high developmental costs, and logistical complexities in mRNA storage and transport, alongside competition from established therapeutic modalities. Intellectual property barriers and supply chain vulnerabilities also pose significant limitations. Nonetheless, the potential for innovation is immense, particularly in improving the stability of mRNA products, developing novel delivery systems (like lipid nanoparticles), and optimizing large-scale manufacturing techniques. These developments could redefine disease management and treatment modalities. The market is highly dynamic, characterized by rapid technological shifts, considerable commercial interest, and extensive R&D activities. For sustained growth, companies should focus on collaborative ecosystems that expedite research and streamline regulatory processes, and they should engage with policy makers to facilitate smoother pathways to market for new mRNA-based innovations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving mRNA Platform Market

The mRNA Platform Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the mRNA Platform Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the mRNA Platform Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the mRNA Platform Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the mRNA Platform Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the mRNA Platform Market

A detailed market share analysis in the mRNA Platform Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the mRNA Platform Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the mRNA Platform Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the mRNA Platform Market

A strategic analysis of the mRNA Platform Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Arcturus Therapeutics Holdings, Inc., Beam Therapeutics Inc., BioNTech SE, Catalent, Inc., CureVac N.V., Daiichi Sankyo Company, Limited, Danaher Corporation, eTheRNA Immunotherapies NV, Ethris GmbH, FUJIFILM Holdings Corporation, Gritstone bio, Inc., In-Cell-Art, Merck KGaA, Moderna Inc., Novo Nordisk A/S, Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi SA, Takara Bio Inc., Telesis Bio Inc., Thermo Fisher Scientific Inc., Tiba Biotech LLC, TriLink BioTechnologies by Maravai LifeSciences, and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the mRNA Platform Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability

6. mRNA Platform Market, by mRNA Type

7. mRNA Platform Market, by mRNA Molecule

8. mRNA Platform Market, by Application

9. mRNA Platform Market, by Indication

10. mRNA Platform Market, by End-User

11. Americas mRNA Platform Market

12. Asia-Pacific mRNA Platform Market

13. Europe, Middle East & Africa mRNA Platform Market

14. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â